Candesartan

Generic Name: Candesartan

Brand Names: Atacand, Atacand Hct

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₀N_₆O_₃

CAS Number: 139481-59-7

Unique Ingredient Identifier: S8Q36MD2XX

Background: Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.

Indication: May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.

Associated Conditions: Hypertension, NYHA Functional Class II-IV Heart Failure

Clinical Trials

CandeSpartan Study. Candesartan Spanish Response-prediction and Tolerability Study

Completed

Conditions: Migraine
Head Pain

Interventions: Drug: Candesartan

First Posted Date: 2019-10-24

Last Posted Date: 2022-12-19

Lead Sponsor: Hospital Clínico Universitario de Valladolid

Target Recruit Count: 85

Registration Number: NCT04138316

Locations: 🇪🇸
Hospital Clínico Universitario Valladolid, Valladolid, Spain

The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions

Phase 1

Completed

Conditions: Bioequivalence

Interventions: Drug: Candesartan Cilexetil 32mg
Drug: Atacand® PROTECT

First Posted Date: 2019-07-09

Last Posted Date: 2019-11-18

Lead Sponsor: Pharmtechnology LLC

Target Recruit Count: 40

Registration Number: NCT04012307

Locations: 🇨🇦
Altasciences Company Inc., Mont-Royal, Quebec, Canada

Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

Phase 4

Completed

Conditions: Hypertension, Hyperlipidemia

Interventions: Drug: Ezetimibe/Rosuvastatin
Drug: Candesartan cilexetil/Amlodipine besylate
Drug: Candesartan cilexetil

First Posted Date: 2019-02-20

Last Posted Date: 2022-05-10

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 127

Registration Number: NCT03847506

Locations: 🇰🇷
Bundang Seoul National University Hospital, Gyeonggi-do, Seongnam-si, Bundang-gu, Korea, Republic of

Effect of Some Drugs on Liver Fibrosis

Phase 3

Recruiting

Conditions: Liver Fibroses

Interventions: Drug: Candesartan
Drug: Ramipril

First Posted Date: 2018-12-10

Last Posted Date: 2018-12-10

Lead Sponsor: Sherief Abd-Elsalam

Target Recruit Count: 45

Registration Number: NCT03770936

Locations: 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt

Candesartan in Peripheral Neuropathy

Phase 2

Terminated

Conditions: Peripheral Neuropathy

Interventions: Drug: Candesartan
Other: Usual care

First Posted Date: 2018-09-28

Last Posted Date: 2021-11-15

Lead Sponsor: University Hospital, Limoges

Target Recruit Count: 9

Registration Number: NCT03688633

Locations: 🇫🇷
CHU Limoges, Limoges, France

Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: QUARTET LDQT
Drug: Candesartan

First Posted Date: 2018-08-21

Last Posted Date: 2025-01-03

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 62

Registration Number: NCT03640312

Locations: 🇺🇸
ACCESS Martin T. Russo Family Health Center, Bloomingdale, Illinois, United States
🇺🇸
Ashland Family Health Center, Chicago, Illinois, United States

Adiposity and Endothelin Receptor Function

Early Phase 1

Active, not recruiting

Conditions: Hypertension

Interventions: Drug: Placebo
Drug: Candesartan

First Posted Date: 2018-07-12

Last Posted Date: 2025-03-25

Lead Sponsor: Augusta University

Target Recruit Count: 25

Registration Number: NCT03583866

Locations: 🇺🇸
Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology, Augusta, Georgia, United States

Bariatric Surgery and Pharmacokinetics of Candesartan

Recruiting

Conditions: Obesity, Morbid

First Posted Date: 2018-03-09

Last Posted Date: 2023-03-27

Lead Sponsor: Norwegian University of Science and Technology

Target Recruit Count: 12

Registration Number: NCT03460327

Locations: 🇳🇴
St. Olavs University Hospital, Trondheim, Norway

Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Candesartan 16mg and Amlodipine 10mg
Drug: HL068 16/10mg

First Posted Date: 2016-12-09

Last Posted Date: 2025-04-04

Lead Sponsor: HanAll BioPharma Co., Ltd.

Target Recruit Count: 42

Registration Number: NCT02988362

Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

Phase 2

Completed

Conditions: Essential Hypertension

Interventions: Drug: Candesartan Cilexetil 16mg
Drug: Candesartan Cilexetil 8mg
Drug: Amlodipine 5mg
Drug: Amlodipine 10mg

First Posted Date: 2016-10-26

Last Posted Date: 2016-11-22

Lead Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Target Recruit Count: 392

Registration Number: NCT02944734

Locations: 🇰🇷
Kyungpook National University Hospital, Joong-gu, Daegu, Korea, Republic of
🇰🇷
Catholic University of Korea Bucheon St. Mary's Hospital, Wonmi-gu, Bucheon, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busanjin-gu, Busan, Korea, Republic of

and more 20 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy